R
Roka Bioscience
Develops molecular assays and instrument systems for the food safety industry
About Roka Bioscience
Roka Bioscience specializes in developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. The company serves food manufacturers, laboratories, and food safety professionals, offering solutions that help mitigate risks, protect brands, and meet increasing testing demands. Operating in the food safety market, Roka Bioscience's business model revolves around selling its proprietary testing systems and consumables. The company generates revenue through the sale of these systems, as well as ongoing sales of assay kits and maintenance services. Established in 2009 as a spin-off from Hologic, Roka leverages advanced technologies such as Target Capture, Amplification, and Hybridization Protection Assay to deliver fully automated, single protocol assays. These technologies enable rapid pathogen detection with enhanced sensitivity and reduced enrichment times, providing significant workflow advantages and walk-away convenience for laboratories.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Lake Forest Park, United States
- Listing
- IPO 2014
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 58.8/100
- Industry
- Food
- Sub-industry
- AgriTech
- Sector
- Food, Testing, Biotechnology, Molecular Biology, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Sep 2016 | $23M | — | Undisclosed | — |
| IPOOther financing | Jul 2014 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $7.2M | 0% |
| 2025 | $7.2M | 0% |
| 2024 | $7.2M | 0% |
| 2023 | $7.2M | 0% |
| 2022 | $7.2M | 0% |
| 2021 | $7.2M | 0% |
| 2020 | $7.2M | — |
Growth signals
Latest recorded traffic for Roka Bioscience is 2.3K monthly website visits, down 50% over the last three months. Roka Bioscience's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Roka Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Roka Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.